AACR Congressional Briefing Covers Precision Medicine, RAS Inhibitors and Personalized Cancer Vaccines

An AACR briefing for US Congress, part of a 95-minute expert lecture, outlined progress in precision oncology: the first molecularly targeted therapy for diffuse midline glioma, protein-degrading agents, seven FDA-approved CAR-T therapies since 2017 including a first for marginal zone lymphoma, and KRAS inhibitors that nearly doubled survival in advanced pancreatic cancer in a Phase III trial. It also highlighted liquid biopsy, a positive Phase III trial of a personalized melanoma neoantigen vaccine, and rising early-onset colorectal cancer rates of more than 6% per year in the US from 2019 to 2023.